A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

This study tests BMS-986460 — a new experimental drug — in men with metastatic castration-resistant prostate cancer (mCRPC), meaning prostate cancer that has spread and is no longer responding to hormone-lowering therapy. **You may be eligible if...** - You have confirmed metastatic prostate cancer that has become resistant to hormone therapy (castration-resistant) - Your PSA level is 2 ng/mL or higher at screening - You have already tried at least one hormone therapy approved for castration-resistant prostate cancer (in addition to ADT) - Your general health is good (ECOG 0–1) **You may NOT be eligible if...** - You have cancer spread to the brain - You have significant heart disease or impaired heart function - You have a major uncontrolled infection or serious psychiatric condition Talk to your doctor to see if this trial is right for you.